September 16, 2024 4:23 PM

ICMR and Panacea Biotec announces initiation of Phase 3 clinical trial for a dengue vaccine in India

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in the country. The trial, which commenced on Wednesday at PGIMS Rohtak, will evaluate the efficacy of DengiAll, India's indigenous tetravalent dengue vaccine developed by Panacea Biotec. Union Health Minister J P Nadda hailed the development as a "critical advancement" in India's fight against dengue. "This collaboration between ICMR and Panacea Biotec not ...